SCHEMBL3752414

SCHEMBL3752414

CN1CCc2c(sc(N)c2-c2nc3ccccc3s2)C1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 8/20 0.66
UHRF1 Q96T88 1/20 0.58
LMNA P02545 3/20 0.57
TP53 P04637 2/20 0.57
RXFP1 Q9HBX9 1/20 0.54
MYC P01106 1/20 0.49
KDM4E B2RXH2 4/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
NPC1 O15118 3/20 0.48
HTT P42858 2/20 0.48
RAB9A P51151 2/20 0.48
USP2 O75604 1/20 0.48
POLB P06746 1/20 0.48
RECQL P46063 1/20 0.48
BLM P54132 1/20 0.48
ALDH1A1 P00352 3/20 0.47
MAPT P10636 3/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13833586 0.85 LMNA (0.60) APEX1UHRF1LMNATP53RXFP1
SCHEMBL13737316 0.85 APEX1 (0.67) APEX1UHRF1TP53MYCKDM4E
SCHEMBL18293231 0.84 APEX1 (0.48) APEX1UHRF1LMNATP53RXFP1
SCHEMBL15101490 0.83 MAPT (0.67) APEX1UHRF1LMNATP53KDM4E
SCHEMBL18293135 0.83 KDM4E (0.47) APEX1UHRF1LMNATP53KDM4E
SCHEMBL14778519 0.82 KDM4E (0.55) APEX1UHRF1LMNATP53RXFP1
SCHEMBL13832568 0.82 APEX1 (0.68) APEX1UHRF1TP53MYCKDM4E
SCHEMBL13832496 0.81 APEX1 (0.67) APEX1UHRF1MYCKDM4EMEN1
SCHEMBL15101513 0.81 ADORA1 (0.55) LMNAMEN1KMT2ANPC1RAB9A
SCHEMBL13833662 0.80 ILK (0.48) APEX1KDM4EMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2023-05-11 US disclosed
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2023-05-11 US disclosed
US-20210188833-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2021-06-24 US disclosed
US-10787444-B2 Compounds for the modulation of myc activity SYROS PHARMACEUTICALS, INC. (US) 2020-09-29 US disclosed
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-06-14 US disclosed
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-06-14 US disclosed
US-8486945-B2 Heterocyclic inhibitors of an Hh-signal cascade, medicinal compositions based thereon and methods for treating diseases caused by the aberrant activity of an Hh-signal system Ivachtchenko, Alexandre Vasilievich (US) 2013-07-16 US disclosed
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. 2013-03-21 US disclosed
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. 2013-03-21 US disclosed
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. 2013-03-21 US disclosed
WO-2012154888-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. (US) 2012-11-15 WO disclosed
US-20100298370-A1 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF RIMONYX PHARMACEUTICALS LTD. (IL) 2010-11-25 US disclosed
WO-2008020438-A2 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF RIMONYX PHARMACEUTICALS LTD (IL) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS HSPA5, PSMG3, VCP APEX1 2669/4885UHRF1 3008/4885LMNA 481/4885
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 APEX1 1196/4885UHRF1 727/4885LMNA 1482/4885
US-20210188833-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 APEX1 1879/4885UHRF1 1090/4885LMNA 1737/4885
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 APEX1 1879/4885UHRF1 1090/4885LMNA 1737/4885
US-10787444-B2 Compounds for the modulation of myc activity MYC, MYCBP, MYCBP2 APEX1 1196/4885UHRF1 727/4885LMNA 1482/4885
US-20100298370-A1 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF HPSE, HDGF, HPGDS APEX1 4756/4885UHRF1 4279/4885LMNA 4715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.